An increasing number of studies show dysregulated SPDEF expression in human cancers, which are associated with different clinical features such as TNM stage, tumor grade, and survival.11 In ovarian cancer, early stage and borderline tumors expressed higher SPDEF than late-stage tumors. This evidence concerns the gene SPDEF and ovarian carcinoma.